Pharmaceutics
Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer.
Taraneh Sadat Zavvar, Giulia Santo, Leonhard Gruber, Ariane Kronthaler, Judith Hagenbuchner, Ira Skvortsova, Inken Piro, Katja Steiger, Vladan Martinovic, Danijela Minasch, Judith Löffler-Ragg, Gianpaolo di Santo, Irene J Virgolini, Elisabeth von Guggenberg
Published: 202610.3390/pharmaceutics18010138
Abstract
Background/Objectives: Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors (NETs), enabling targeted radiation delivery via radiolabeled peptides. Small cell lung cancer (SCLC) remains a major therapeuti…
Preview only. Read the full abstract at the source